BioCentury | Mar 25, 2021
Regulation
March 24 Quick Takes: A first for Twist, Biotia and a refusal-to-file letter for Novo; plus Novartis’ radioligand, Zealand, four Japan approvals and more
...for a targeted therapy.With Zegalogue approval, Zealand preparing first U.S. launchFDA approved Zegalogue dasiglucagon from Zealand Pharma A/S...
...suspension, arikace, slit amikacin) 177Lu-PSMA-617, Lu177-PSMA-617 (PSMA-617, AAA617, [18F]PSMA-1007) Vitrakvi, larotrectinib (LOXO-101) Uplizna (inebilizumab, MEDI-551, MT-0551) Merck & Co. Inc. Zealand Pharma A/S Incyte...
...suspension, arikace, slit amikacin) 177Lu-PSMA-617, Lu177-PSMA-617 (PSMA-617, AAA617, [18F]PSMA-1007) Vitrakvi, larotrectinib (LOXO-101) Uplizna (inebilizumab, MEDI-551, MT-0551) Merck & Co. Inc. Zealand Pharma A/S Incyte...